Healthcare

GeminX Pharmaceuticals specializes in the discovery and development of novel small-molecule cancer therapeutics based on the regulation of apoptosis, the body’s natural ability to destroy injured or damaged cells. GeminX’s lead product, GX15-070, is a small-molecule, pan-inhibitor of Bcl-2 proteins. GeminX is also developing small molecules that induce apoptosis in p53-defective cancers.

• Developing first-in-class cancer therapeutics based on reinitiating programmed cell death, or apoptosis, and the inhibition of metabolism in cancerous cells
• Focused on small molecules that target specialized pathways for cancer, including key regulators in the genesis and progression of cancer